| Name: | Upadacitinib |
|---|---|
| CAS:: | 1310726-60-3 |
| Molecular Formula: | C17H19F3N6O |
| Standard: | In-house |
| Documentation: | CDMF |
| Development stage: | Commercialization |
Upadacitinib
Upadacitinib is an oral selective inhibitor of Janus associated kinase 1 (JAK-1) that is used in the therapy of moderate-to-severe rheumatoid arthritis. Upadacitinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients.